Donald J. Hayden Jr. - 17 May 2022 Form 4 Insider Report for Theseus Pharmaceuticals, Inc.

Role
Director
Signature
/s/ Bradford Dahms - Attorney-in-Fact
Issuer symbol
N/A
Transactions as of
17 May 2022
Net transactions value
$0
Form type
4
Filing time
18 May 2022, 16:27:58 UTC
Next filing
03 Jan 2023
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction THRX Stock Option (right to buy) Award $0 +60,000 $0.000000 60,000 17 May 2022 Common Stock 60,000 $8.02 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The options are subject to a service-based vesting requirement, which shall be satisfied over a three-year period with 1/36th of the options vesting on June 17, 2022 and 1/36th of the options vesting monthly thereafter, subject to the Reporting Person's continuous service with the issuer on each such vesting date.